Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03728569 · ClinicalTrials.gov registry record · Early Phase 1
Skin Barrier Dysfunction and the Role of Skin Barrier Restoration
A Early Phase 1 study, sponsored by University of Michigan.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
NCT03728569: Clinical Trial Early Phase 1 study, sponsored by University of Michigan.
NCT03728569 is a Early Phase 1 study that was terminated before completion, run by University of Michigan. The registered enrollment target is 14 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03728569, a Early Phase 1 study, was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The objective of this exploratory study is to gain an understanding of cutaneous and systemic inflammation and how restoration of the skin barrier through the use of moisturizer may restore the skin barrier function and reduce systemic inflammation in elderly humans compared to the young. The exploratory study will consist of three visits per subject. Subjects will be instructed to apply a moisturizer (Vanicream Moisturizing Skin Cream) over the entire skin surface from the neck down twice daily for up to 30 days.
Primary Outcome
Trans-epidermal water loss (TEWL) will be performed on the upper arm and buttocks at Visits 1 and 2. This instrument will measure the amount of water that is lost through the skin. The change in skin hydration status in each subject will be assessed and compared between groups.
Interventions
- OTHER Vanicream Moisturizing Skin Cream
- OTHER Vanicream Cleansing Soap
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-05-16 |
| Est. Completion | 2021-02-01 |
| Phase | Early Phase 1 |
Why NCT03728569 stopped before completion
NCT03728569 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Vanicream Moisturizing Skin Cream is the first listed.
NCT03728569 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03728569 about?
NCT03728569 is a clinical study titled "Skin Barrier Dysfunction and the Role of Skin Barrier Restoration". The objective of this exploratory study is to gain an understanding of cutaneous and systemic inflammation and how restoration of the skin barrier through the use of moisturizer may restore the skin barrier function and reduce systemic inflammation in elderly humans compared to the young. The explor...
What is the current status of trial NCT03728569?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2018-05-16. Estimated completion is 2021-02-01.
What interventions are being tested in trial NCT03728569?
The interventions under investigation include: Vanicream Moisturizing Skin Cream (OTHER), Vanicream Cleansing Soap (OTHER).
Who is sponsoring clinical trial NCT03728569?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03728569's enrollment target sits among peer trials
14 1474th of 2000 higher than 498 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy